Skip to main content
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2014 May 8;14(2-3):103–117. doi: 10.3233/CBM-130328

The value of new high-throughput technologies for diagnosis and prognosis in solid tumors

Rosamaria Pinto a, Simona De Summa a, Daniela Petriella a, Oana Tudoran b, Katia Danza a, Stefania Tommasi a,*
Editors: Ioana Berindan Neagoex, Angelo Paradisoy
PMCID: PMC12928372  PMID: 24878811

Abstract

Advances in our understanding of the molecular basis of tumors, as well as in the technology of DNA analysis, are rapidly changing the landscape of these diseases. Traditional approaches such as sequencing methods and arrays have too many limits. These have been overcome by the advent of next generation sequencing (NGS) methods which facilitate and accelerate the analysis of multiple genes and samples.

These technologies allow new applications in molecular biology and medicine, for example precise analysis of RNA transcripts for gene expression; profiling of small RNAs, DNA methylation patterns and histone modification analysis; identification of splicing isoforms and of DNA regions that interact with regulatory proteins; pharmacogenomics studies and so on.

In this review we describe recent applications of NGS in genomics, transcriptomics and epigenomics for a better comprehension of solid tumor metabolisms.

Keywords: Next generation sequencing, genomics, transcriptomics and epigenomics

Full Text

The Full Text of this article is available as a PDF (171.8 KB).


Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES